Proactive Investors - Run By Investors For Investors

e-Therapeutics enhances its AI technology capabilities as it signs two collaboration deals

The tie-ups are with University of Cambridge spin-out Intellegens and Manchester-based Biorelate
technology
No financial details of the agreements were disclosed

Computer-based drug developer e-Therapeutics PLC (LON:ETX) has signed collaboration deals which will enhance and extend its artificial intelligence (AI) technology capabilities.

Both Intellegens and Biorelate have AI tools which, after pilot studies, have been shown to complement ETX’s existing computational network-driven drug discovery (NDD) technology.

READ: e-Therapeutics sees cash burn and losses fall in first half as new boss’ plans take shape

Intellegens is a spin-out from the University of Cambridge that has developed a unique AI method for training neural networks from incomplete data.

The tie-up will allow ETX to apply Intellegens' technology to the predication and error correction of large-scale biological and chemical data and will enhance ETX’s existing proprietary databases.

The tech will also be used to develop a novel computationally guided approach to medicinal chemistry.

As for Manchester-based Biorelate, it uses AI to create databases by analysing published literature around a certain topic – digging out the most important and relevant pieces of information from masses of research journals and papers.

The aim of the collaboration is to directly feed this knowledge into e-Therapeutics' NDD engine which should help in the pursuit of novel disease mechanisms.

READ: e-Therapeutics pioneering the development of improved new drugs with a focus on cancer

“We already utilize machine learning heavily in our discovery platform to augment empirical biological and chemical data,” said ETX's head of discovery informatics Jonny Wray.

“These partnerships will enhance and extend our internal capabilities via collaborations with companies at the cutting edge of AI research and application.”

View full ETX profile View Profile

e-Therapeutics plc Timeline

CN Video
March 28 2018

Related Articles

surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use